Article
Activation of ERBB4 in glioblastoma can contribute to increased tumorigenicity and influence therapeutic response
2018-06-12
Abstract excerpt
Glioblastoma (GBM) is often resistant to conventional and targeted therapeutics. ERBB4 is expressed throughout normal brain and is an oncogene in several pediatric brain cancers; therefore, we investigated ERBB4 as a prognostic marker and therapeutic target in GBM. Using RT-qPCR, we quantified mRNA encoding total ERBB4 and known ERBB4 variants in GBM and non-neoplastic normal brain (NNB) samples. Using immunohisto...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b621f3b0-4a07-5eed-8aa6-a88eaf87518f
- DOI
- 10.20944/preprints201806.0197.v1
